Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 204 participants.

Also called NCT04790513

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 204 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04790513
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04790513. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-22 (actual); primary completion 2022-09-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
Acronym
LIBerate-H2H
Condition
Hypercholesterolemia
Condition
Cardiovascular Diseases
Intervention (Biological)
lerodalcibep
Intervention (Biological)
evolocumab
Intervention (Biological)
alirocumab
Lead sponsor
LIB Therapeutics LLC (class: industry)

Record details

Record id
cardio:ct-nct04790513
Content hash
44b7842e5ea34aecbb1125607b406009660bb3892979b7b51539b4bcd0d846e3